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ABSTRACT
Glioblastoma (GBM) is the most common primary malignant brain tumor in 
adults. The challenging problem in cancer treatment is to find a way to upregulate 
radiosensitivity of GBM while protecting neurons and neural stem/progenitor cells 
in the brain. The goal of the present study was upregulation of the cytotoxic effect 
of γ-irradiation in GBM by non-psychotropic and non-toxic cannabinoid, cannabidiol 
(CBD). We emphasized three main aspects of signaling mechanisms induced by CBD 
treatment (alone or in combination with γ-irradiation) in human GBM that govern 
cell death: 1) CBD significantly upregulated the active (phosphorylated) JNK1/2 
and MAPK p38 levels with the subsequent downregulation of the active phospho-
ERK1/2 and phospho-AKT1 levels. MAPK p38 was one of the main drivers of CBD-
induced cell death, while death levels after combined treatment of CBD and radiation 
were dependent on both MAPK p38 and JNK. Both MAPK p38 and JNK regulate the 
endogenous TRAIL expression. 2) NF-κB p65-P(Ser536) was not the main target of 
CBD treatment and this transcription factor was found at high levels in CBD-treated 
GBM cells. Additional suppression of p65-P(Ser536) levels using specific small 
molecule inhibitors significantly increased CBD-induced apoptosis. 3) CBD treatment 
substantially upregulated TNF/TNFR1 and TRAIL/TRAIL-R2 signaling by modulation 
of both ligand and receptor levels followed by apoptosis. Our results demonstrate 
that radiation-induced death in GBM could be enhanced by CBD-mediated signaling in 
concert with its marginal effects for neural stem/progenitor cells and astrocytes. It 
will allow selecting efficient targets for sensitization of GBM and overcoming cancer 
therapy-induced severe adverse sequelae.
INTRODUCTION
External beam radiation therapy alone or in 
combination with chemotherapy (using Temozolomide, 
a DNA methylating agent with DNA damage activity) is 
the main treatment procedure for brain tumors including 
glioblastoma [1, 2]. Such treatment also causes severe 
damage to normal brain tissues. While normal glial cells 
exhibit a substantial degree of radioresistance, adult 
neurons and endothelial cells could be significantly injured 
by ionizing radiation. Additionally, oligodendrocyte 
precursor cells (OPC), neural stem and progenitor cells 
(NSC/NPC) having significant proliferative capacities 
are also highly sensitive to radiation therapy alone or 
especially in combination with chemotherapy. Clinical 
observations and experiments with animals further 
demonstrated that cranial irradiation for brain tumor 
treatment may result in encephalopathy, as well as strong 
cognitive and memory deficits [3–10]. 
Glioblastoma (GBM) is the most common primary 
malignant brain tumor in adults affecting more than 
23,000 new patients in the US each year with estimated 
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number of death 16,050 in the year 2016 (http://seer.
cancer.gov/statfacts/html/brain.html#risk). Despite 
advances in therapy, outcomes remain poor with a median 
survival rate of 12–15 months after initial diagnosis [11]. 
The challenging problem in brain cancer therapy is to find 
a way to radiosensitize GBM while protecting neurons, 
NSC/NPC and OPC or elucidate new ways of treatment. 
Gliomas are thought to arise from NSC/NPC and 
young astrocytes [12]. Numerous progression-associated 
genetic alterations are very common to different types 
of gliomas and glioblastomas. Investigations of the 
somatic genomic landscape of GBM’s demonstrated 
a connection between gene alteration and signaling 
pathway modifications in GBM cells, which include 
receptor tyrosine kinases (RTK) pathways (EGFR1, 
FGFR2 or PDGFRA), PI3K/PTEN-AKT-mTORC1 
pathway, MAPK pathways, p53 pathway, RB1 pathway 
(RB1, CDK4 and CDK6) [9, 13] and IKK-NF-κB 
pathway with frequent inactivation of inhibitor kappa-B 
(NFKBIA) [14, 15]. These genetic alterations together 
with numerous epigenetic modifications could establish 
resistance to treatment of GBM. Furthermore, quick 
rewiring of signaling networks that substantially changes 
gene expression in GBM cells and provide resistance to 
treatment may occur through “adaptive” mechanisms 
before clonal selection in the heterogeneous GBM cell 
populations [16]. 
Treatment with ionizing radiation induces the 
generation of reactive oxygen species (ROS), which affect 
genomic DNA in the nucleus (resulting in DNA damage 
followed by a DNA damage response) and initiate cell 
signaling pathways in the cytoplasm that control gene 
expression in the regulation of cell survival/death [17, 18]. 
The tumor microenvironment is actively involved in the 
control of cell signaling pathways and gene expression 
in cancer cells before and after treatment by irradiation 
using intercellular communications [19]. On the other 
hand, beside direct lethal effects on target cells, γ-radiation 
induced expression and secretion of cytokines, death 
ligands, prostaglandins and endocannabinoids establishing 
inverse communication between treated tumor cells and 
non-irradiated bystander cells of the microenvironment, as 
well as of remote regions in the brain containing OPC and 
NSC/NPC [20–22]. These secondary non-targeted effects 
could significantly affect normal cells and upregulate 
direct destructive effects of radiation [20, 21, 23]. 
Human GBM’s are extremely heterogeneous at both 
levels of regulation during carcinogenesis: i) genomic 
alterations, including chromosome rearrangement, 
deletions, and mutations; ii) substantial epigenetic changes 
that control gene expression. The integrated genomic 
analysis built a dataset from 200 GBM’s and normal brain 
samples allowed to identify four glioblastoma subtypes 
named proneural, classical, mesenchymal and neural each 
characterized by a distinct gene expression signature [24]. 
i) The proneural subtype was associated with Platelet-
derived growth factor receptor (PDGFRA) abnormalities, 
IDH1 and TP53 mutations. ii) The classical subtype was 
strongly associated with the astrocytic signature and 
contained all common genomic aberrations observed in 
GBM, such as chromosome 7 amplifications, chromosome 
10 deletions, EGFR amplification, deletion of the TP53-
stabilising isoform of the cyclin-dependent inhibitor 
CDKN2A/ARF. iii) The mesenchymal subtype was 
characterized by NF1 abnormalities quite often together 
with PTEN mutations/deletions. Furthermore, genes in 
the TNF superfamily and NF-κB pathway were highly 
expressed in this subtype together with the expression 
of astrocyte and mesenchymal markers. It was the most 
aggressive subtype with the poor outcome of patients. iv) 
The neural subtype was typified by expression of neuron 
markers with relatively low levels of mutated driver genes, 
such as TP53, PTEN, NF1, EGFR1 and IDH1 [24]. 
Three human glioblastoma cell lines, U87MG, 
U118MG, and T98G used in the current study contain 
numerous rearrangements of chromosomes and substantial 
changes in the genomic landscape. However, they 
represent poorly subtypes of primary human gliomas. On 
the other hand, U87MG and U118MG were used as parent 
lines for selections of sublines of typical mesenchymal 
pattern cells [25, 26]. In spite of obvious restriction of 
similarity between glioblastoma cells in vivo and in 
cell culture conditions, a recent comprehensive study 
highlighted the importance of established cell lines that 
represent the same pattern of gene alteration as cancer 
cells in vivo [27]. In the present study, we elucidate the 
killing effects and mechanisms of sensitization of GBM 
cells to treatment through signaling pathways induced 
by the exogenous cannabinoids that could regulate the 
signaling cascades initiating death of cancer cells [28, 29]. 
Numerous investigations of the last decade demonstrated 
cytotoxic effects of cannabinoids, including non-toxic 
cannabidiol (CBD) without psychogenic activity, on 
human and mouse glioblastoma cells [29–33]. However, 
the signaling mechanisms that are involved in regulation 
of glioblastoma cell death and survival by CBD are still 
not completely elucidated. There is interest to investigate 
possible radiosensitization of human GBM cells by 
combined treatment of CBD and γ-irradiation with further 
use of specific inhibitors of the distinct signaling pathways 
that could enhance or suppress cell death.
 The endocannabinoid system regulates general and 
neuro-specific function through cannabinoid receptor-1 
(CB1), which is preferentially expressed in neurons but 
also in other types of cells, and cannabinoid receptor-2 
(CB2), which is preferentially expressed on lymphocytes, 
as well as in many other cells. Glial cells and gliomas 
possess both CB receptors [34, 35]. Endocannabinoids 
and ∆9-tetrahydrocannabinol ∆THC have a high affinity 
for both cannabinoid receptors, CB1 and CB2, which are 
members of the superfamily of Seven-transmembrane-
domain G-protein-coupled receptors that induce upon 
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activation signaling cascades in the cells. However, due to 
the very low affinity of CBD for both CB1 and CB2, CBD-
induced signaling effects in GBM cells were suggested 
to be mostly CB1/2-receptor-independent [30, 32]. In 
spite of this feature, a downstream cross-talk between 
CBD-mediated signaling and CB1- and CB2-dependent 
signaling cascades might occur in an indirect manner using 
an unknown mechanism [36, 37]. In contrast to relatively 
normal functions in neuronal and glial cells, the early 
effects of ∆THC-activated CB1/2 receptors in glioma/ 
glioblastoma cells included a substantial upregulation 
of ceramide levels in the endoplasmic reticulum (ER) 
that resulted in the ER-stress response followed by 
autophagy and apoptosis [38, 39]. On the other hand, CBD 
treatment induced massive ROS production accompanied 
by activation of both ROS-dependent signaling and the 
protective antioxidant systems in glioma cells linked with 
the subsequent induction of autophagy and activation of 
the mitochondrial apoptotic pathway [40–42]. CBD can 
also induce cancer cell apoptosis via activation of p53-
dependent apoptotic pathways in cancer cells with wild-
type p53 [43]. In contrast, CBD treatment of nonmalignant 
brain cells was not linked with induction of apoptosis [44].
Combined treatment of brain cancers could be a 
way to increase radiosensitivity of GBM while protecting 
neurons and NSC/NPC. The main goal of the present 
study was to investigate enhanced cytotoxic effects of 
γ-irradiation in GBM by non-psychotropic and non-toxic 
cannabinoid, cannabidiol (CBD) and to elucidate cell 
signaling pathways that mediate these effects. 
RESULTS
Combined treatment of glioblastoma cells by 
cannabidiol (CBD) and γ-irradiation
Treatment of GBM cells with high doses of 
γ-radiation suppressed cell proliferation and induced a 
mixed type of cell death mainly through cell cycle arrest, 
mitotic catastrophe, apoptosis, and secondary necrosis. 
Temozolomide, a DNA methylating agent with a strong 
DNA damage activity further amplified these processes 
[2, 17, 45]. As an alternative modality to increase the lethal 
effects of γ-irradiation, we co-treated human glioblastoma 
(GBM) cells with cannabidiol (CBD, 5–20 µM) suggesting 
strong additional effects on regulation of cell signaling, 
proliferation, and death. Three human glioblastoma lines, 
U87MG (HTB-14), U118MG (HTB-15), and T98G (CRL-
1690) used in the present study were obtained from the 
ATCC. These lines exhibit high protein expression of 
cannabinoid receptors, CB1 and CB2 [34, 35]. 
Since U87MG glioblastoma cells contained a 
normal variant of p53 while U118MG had mutated p53, 
we expected a different response of these cell lines to 
combined treatment, due to decreased activity of the 
mitochondrial apoptotic pathway in U118MG cells. First, 
we determined changes in the levels and activities of the 
main signaling proteins at 4 h and 16 h after treatment 
with 10 µM CBD and γ-radiation at 5 Gy, alone or in 
combination (Figure 1A–1C), and then the late events 
(48–72 h) linked with cell death by apoptosis in U87MG 
and U118MG cells after dose-dependent-treatment by 
CBD (5–20 µM) and γ-irradiation (5 Gy) (Figure 1D, 1E). 
CBD in 0.1% DMSO or control 0.1% DMSO were added 
to the cell cultures 30 min before irradiation. Change of 
p53 protein levels demonstrated efficacy of γ-irradiation: 
in both GBM lines, U87MG with the normal p53 and 
U118MG with a mutated and more stable variant of p53, 
protein levels of p53 were additionally upregulated after 
irradiation (Figure 1A, 1B). T98G cells also had mutated 
p53 and destroyed mitochondrial apoptotic pathway [46]. 
The active phospho-Ser568-p65 NF-κB levels 
were relatively stable in U87MG and slightly increased 
after CBD or combined treatment (4 h) of U118MG cells 
(Figure 1A). A modest downregulation of the high basal 
AKT1 activity (represented by phospho-Ser473-AKT1 
levels) was detectable 4 h after treatment with CBD, alone 
or in combination with radiation, in both lines. Phospho-
ERK1/2 levels were also relatively stable in U87MG 
cells 4 h after indicated treatments while these levels 
demonstrated modest increase after CBD and γ-irradiation 
treatments in U118MG cells (Figure 1A). In contrast, 
upregulation of phospho-JNK1/2 levels was observed in 
both GBM lines 4 h after treatment with γ-irradiation or 
CBD, alone or, especially, in combination, but with the 
characteristic difference between these lines: a dramatic 
increase of phospho-JNK1/2 levels in U87MG cells and 
less pronounced and variable increase in U118MG cells 
(Figure 1A). Phospho-(T180/Y182)-p38 MAPK levels 
modestly increased 4 h after treatment with CBD or 
γ-irradiation in both cell lines (Figure 1A). 
Signaling events in U87MG cells after 16 h 
exposure with CBD and γ-radiation included upregulation 
of p53 but relatively stable levels of total and active NF-
κΒ phospho-Ser536-p65 (Figure 1B). Substantial changes 
observed after 16 h of treatment also included a strong 
downregulation of phospho-AKT levels (Figure 1B), a 
notable downregulation of phospho-ERK1/2, a significant 
upregulation of phospho-JNK1/2 and phospho-MAPK 
p38 levels. Pronounced negative effects of CBD treatment 
on AKT and ERK1/2 activities were previously described 
[26, 47], however, we would like to highlight a strong 
activation of JNK1/2 and MAPK p38 in these conditions 
(Figure 1B). On the other hand, a modest upregulation of 
JNK1/2 and p38 activities and a substantial increase in 
p53 protein levels were characteristic for U87MG cells 
after γ-irradiation alone. In general, synergistic effects 
of CBD and γ-irradiation on the main signaling proteins 
were observed for the early upregulation of active 
JNK1/2, the late downregulation of ERK1/2 activities 
and the late upregulation of proapoptotic proteins, BAX 
and TRAIL (Figure 1B). The significance of TRAIL 
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expression for cell death regulation will be elucidated 
in the subsequent experiments. The late activation of 
MAPK p38 was dependent most from CBD while impact 
of γ-irradiation was modest. Additionally, caspase-3-
dependent cleavage of PARP-1, an indicator of apoptotic 
commitment, was well pronounced 16 h after combined 
treatment of GBM cells (Figure 1B). A substantial 
upregulation of heme oxygenase-1 (HO1) levels that was 
indicative of protection activity against oxidative stress 
was observed 4–16 h after treatment of U87MG cells by 
CBD alone or in combination with radiation (Figure 1B). 
A difference in the levels of inducible JNK1/2 activities 
between U87MG and U118MG cells was maintained 
after overnight treatment; furthermore, levels of ERK1/2 
activities were decreased in both glioma lines after 
overnight treatment (Figure 1C).
Dose-dependent effects of CBD (5–10 µM) on 
induction of apoptosis occurred with relatively similar 
kinetics in both GBM lines (Figure 1D, 1E). However, 
additional significant effects of γ-irradiation (5 Gy) on 
CBD-induced apoptosis 48 h and 72 h after treatment were 
detected only in U87MG cells, probably, due to the intact 
p53-BAX pro-apoptotic system in these cells. After 48 h 
of combined treatment (20 µM CBD and 5 Gy) apoptotic 
levels were close to 50%, and after 72 h they achieved 
almost 90% in U87MG cells and almost 70% in U118MG 
cells (Figure 1D, 1E). In general, CBD-induced cell death 
by apoptosis was a slowly developing process in gliomas 
Figure 1: Changes in cell signaling proteins and induction of apoptosis in U87MG and U118MG glioblastoma cells 
following treatment with γ-irradiation and CBD, alone or in combination. (A, B, C) Western blot analysis of cell signaling 
proteins 4 h and 16 h after combined treatment of U87MG and U118MG cells with CBD (10 µM) and γ-irradiation (5 Gy). CBD was 
diluted in DMSO; 0.1% DMSO served as a vehicle; CBD and DMSO were added to the cell cultures 30 min before irradiation. (D, E) Cell 
cycle-apoptosis analysis of U87MG and U118MG cells 48 and 72 h after combined treatment with increased concentrations of CBD and 
γ-radiation (5 Gy). CBD (diluted in DMSO) was added 30 min before irradiation. Control cells (CBD, 0) were treated with 0.1% DMSO 
48–72 h after treatment; then cell nuclei were stained with PI and DNA content was determined using the flow cytometry. Apoptotic cells 
and secondary necrotic cells (originated from apoptotic cells) were in the pre-G1 region. Pooled results of four independent experiments 
of dose-dependent effects of CBD and irradiation (5 Gy) for U87MG and U118MG cells are shown. Error bars represent means ± S.D. 
(p < 0.05, Student’s t-test). Stars indicate significant differences in apoptotic levels between non-irradiated and irradiated U87MG cells; 
arrows indicated significant differences between irradiated U87MG cells pending CBD concentration; circles indicate significant differences 
in apoptosis between non-irradiated U118MG cells in the presence of CBD.
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suggesting the participation of the secondary mechanism 
of amplification of cell death.
However, it was possible to detect the early effects 
of CBD and γ-irradiation in the induction of apoptosis for 
U87MG cells 16 h after exposure. Indeed, beside caspase-
3-dependent PARP-1 cleavage (Figure 1B), Annexin-
V-FITC and PI staining followed by FACS analysis 
demonstrated low but statistically significant apoptotic 
and the secondary necrotic levels (Annexin-V-positive 
and Annexin-V-negative, respectively) 16 h after CBD 
treatment (at 10 µM) or γ-irradiation (5 Gy) alone or, 
especially, in combination (Figure 2A). Immunostaining 
of adherent glioma cells using anti-total ERK Ab (the 
left panel of Figure 2B) and phase-contrast microscopy 
of the native glioma cell cultures (the right panel) did 
not reveal notable changes in cell morphology 16 h after 
treatment but demonstrated strong death-induced effects 
of CBD 48–72 h after treatment including damage of cell-
cell interaction and appearance of dead cell bodies (not 
neurospheres). Finally, combined treatment (after 48–72 
h) resulted in low cell survival and strong death-related 
changes in the cell cultures (Figure 2B). 
Interestingly, there was a critical difference in 
the consequence of combined treatment of GBM cells 
depending on the sequence of treatment. So, we observed 
strong effects of CBD pretreatment that occurred 30 
min before exposure to γ-radiation on the final levels of 
apoptosis (Figure 2C). A change of the order of treatment 
of U87MG cells using the initial γ-irradiation (10 Gy) and 
delayed addition of CBD (24 h after irradiation) lead to an 
actual downregulation of radiation-induced apoptosis by 
CBD (Figure 2D). The significance of this phenomenon 
will be investigated in additional experiments.
As was previously demonstrated using glioma 
cells, the primary action of CBD included a substantial 
upregulation of ROS production [40, 48]. Using lipid-
soluble antioxidant α-Tocopherol (Vitamin E; VitE) 
that could penetrate into the glioma cells through 
the cell membrane at a dose 50 µM, we observed 
substantial suppression of CBD-induced apoptosis in 
U87MG and less pronounced in U118MG cells, as was 
previously reported [40, 48], and partial suppression of 
apoptosis induced by combined treatment of CBD and 
γ-irradiation in both cell lines (Figure 2G, 2H). At the 
levels of signaling proteins, we observed a stable NF-
κB p65-P activity together with restoration of CBD-
induced downregulation of phospho-AKT and phospho-
ERK levels 16 h after co-treatment of CBD and VitE 
(Figure 2E). Interestingly, VitE strongly downregulated 
CBD-induced JNK1/2-cJUN phosphorylation 4–16 h after 
co-treatment while its effect on downregulation of MAPK-
p38-ATF2 phosphorylation was modest and only 4 h after 
treatment (Figure 2E). Results obtained further indicated 
a distinctive role of JNK, as well as MAPK p38, ERK and 
AKT in mediation of CBD-induced oxidative stress and 
may serve as a foundation for the subsequent experiments. 
Furthermore, VitE co-treatment suppressed activation of 
caspase-3 via decreased p17 (active form) production 
and partially downregulated caspase-3-mediated PARP1 
cleavage (Figure 2F). Our data demonstrated partial 
protective effects of VitE against CBD- and (CBD+5Gy)-
induced apoptosis in U87MG cells (Figure 2G) as well as 
in U118MG cells (Figure 2H).
In contrast to glioblastoma cells, human neural 
stem/progenitor cells (NSC/NPC), which were also known 
as the ancestors of glioma/glioblastoma (Figure 3A–3C), 
and immortalized human fetal astrocytes (IHFA) did 
not respond by induction of notable levels of apoptosis 
following CBD treatment. Furthermore, ionizing 
irradiation at 5 Gy in combination with 5–15 µM CBD 
(added 0.5 h before irradiation), which notably increased 
radiation-induced apoptotic death levels in U87MG cells 
(see Figure 1D and 1E), did not significantly change 
the initial radiation-induced death levels for NSC/
NPC and caused only modest alteration in apoptotic 
levels of immortalized human fetal astrocytes (IHFA) 
(Figure 3D, 3E). Interestingly, CBD treatment (10 µM) 
caused downregulation of SOX2 levels in NSC/NPS 
(Figure 3A). It was followed by acceleration of neuronal 
differentiation of NSC/NPC (treated at low or high 
cell density), as was determined by an increased ratio 
of Doublecortin (green), a neuronal marker, to Nestin 
(red), an early neuroprogenitor marker (Figure 3F, 3G). 
The similar effects on neuronal differentiation were 
previously observed for endocannabinoids [34]. Hence, 
there was an obvious preference of CBD to use different 
programs for initiation of apoptotic cell death in GBM 
cells and for control of the normal functions in NSC/
NPC and astrocytes. This observation could be a basis for 
experiments in vivo to assess the optimal ratio between 
CBD and a dose of γ-irradiation for combined treatment 
of glioblastoma with minimal damaging effects for normal 
cells in the brain.
Since high total doses of γ-irradiation (46–60 
Gy) were used in clinics for radiotherapy of human 
glioblastoma [49], we further assessed killing effects of 
CBD and γ-irradiation on glioblastoma cells following 
treatment at increased radiation dose (10 Gy) and 
CBD (20 µM). In these conditions, we observed an 
additional upregulation of CBD-induced apoptosis not 
only in U87MG cells but also in U118MG cells if CBD 
pretreatment was before irradiation (Figure 4A). On the 
other hand, delayed addition of CBD 16 h after irradiation 
again down-regulated radiation-induced apoptosis in both 
glioblastoma lines (Figure 4B). Western blot analysis 
further confirmed well-pronounced upregulation of 
JNK and moderate increase of MAPK p38 activities in 
glioblastoma lines after such treatments (Figure 4C). 
We used a pancaspase inhibitor zVAD-fmk (50 µM 
in 0.1% DMSO) to suppress apoptotic cell death induced 
CBD (20 µM) alone or in combination with irradiation (10 
Gy) (Figure 4D). Pretreatment with zVAD-fmk, which was 
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added to the glioblastoma medium 1 h before treatment, 
substantially downregulated % of pre-G1 cells with 
apoptotic nuclei, further confirming apoptotic commitment 
after combined treatment of glioblastoma cells under high 
stress conditions. Levels of total cell death resistant to 
zVAD-fmk treatment might include secondary necrotic 
cells. However, co-treatment with Necrostatin (50 µM), 
an inhibitor of RIP1 kinase and necroptosis [50], did not 
notably change total cell death levels in CBD-treated 
glioma cells (data not shown), highlighting the absence 
of the major role for programmed necrosis/necroptosis in 
these conditions.
Differential role of ERK, MAPK p38, JNK and 
AKT in modulating CBD-induced death of 
glioblastoma cells
What is the role of cell signaling mechanisms, 
which are involved in modulating cell survival and 
apoptosis in GBM after CBD treatment? To address this 
Figure 2: Regulation of cannabidiol (CBD)- induced apoptosis in human U87MG glioblastoma cells. (A) Annexin-V-FITC 
and PI staining of U87MG glioblastoma cells 16 h after treatment by CBD and γ-irradiation (5 Gy) alone or in combination was performed 
with the subsequent FACS analysis. (B) Immunostaining of total ERK (48 h) and phase-contrast microscopy of U87MG cells 48 h (72 h) 
after indicated treatment. Typical images are shown. Bar = 50 μm. (C) Dose-dependent effect of co-treatment by CBD on radiation-
induced apoptosis (5 Gy) in U87MG glioblastoma cells. CBD in DMSO solution was added 30 min before irradiation. Cell cycle-apoptosis 
analysis was performed using PI staining of DNA and flow cytometry. Pooled results of four independent experiments are shown 72 h after 
treatment. Error bars represent means ± S.D. (p < 0.05, Student’s t-test). Stars indicate a significant difference between non-irradiated and 
irradiated cells; arrows indicate a significant effect after combined treatment with CBD (20 µM) and γ-irradiation (5 Gy). (D) U87MG 
cells were first irradiated at 5 Gy; 16 h after irradiation CBD and DMSO were added for an additional 48 h. Stars indicate a significant 
difference between non-irradiated and irradiated cells; black arrows indicate a significant negative effect after combined treatment with 
CBD (20 µM) and γ-irradiation (5 Gy). (E, F) Effect of antioxidant Vitamin E (50 µM) on CBD-induced signaling in U87MG cells 4,16 
and 48 h after CBD treatments; Vitamin E (VitE) in ethanol was added 15 min before CBD. Western blot analysis was performed using 
the standard procedures. (G, H) Effects of VitE (50 µM) on apoptosis induced by CBD or combined treatment of CBD and γ-irradiation 
in U87MG and U118MG cells. Stars indicate a significant down-regulation of CBD-induced apoptosis in the presence of Vitamin E (50 
µM); arrows indicate a significant down-regulation of apoptosis after combined treatment with CBD (20 µM) and γ-irradiation (5 Gy) in 
the presence of VitE.
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question, we assessed effects of small molecule inhibitors 
of several crucial signaling pathways on CBD-induced 
signaling cascades: 1) BMS34554, an inhibitor of IKKβ, 
that protected IκΒ from degradation resulting in down-
regulation of NF-κB nuclear translocation, a decrease 
of the active nuclear NF-κB p65 levels and suppression 
of p65-Ser536 phosphorylation; 2) LY294002, an 
inhibitor of PI3K, that suppressed the downstream AKT1 
phosphorylation/ activation and finally affected numerous 
AKT downstream targets, including mTORC1 and IKKα; 
3) U0126, an inhibitor of MEK1/2, that suppressed 
downstream ERK1/2 phosphorylation and activation; 
4) SP600125, an inhibitor of the enzymatic activity 
of JNK1-3 with the downstream suppression of cJUN 
phosphorylation; and 5) SB203580, an enzymatic inhibitor 
of MAPK p38 activity that could suppress activities of 
numerous downstream targets. Based on the results of our 
previous publication [22], we observed specific inhibition 
of AKT1 phosphorylation by LY294002 (50 µM); a 
downregulation of NF-κB p65-Ser536 phosphorylation 
only by combined treatment of BMS344551 (20 µM) 
and LY294002 (50 µM); specific inhibition of ERK1/2 
phosphorylation by U0126 (10 µM) in both glioblastoma 
lines (Figure 5A).
Next, we were focused on JNK and MAPK p38 
signaling pathways and their downstream targets, such as 
transcription factors cJUN and ATF2. Strong upregulation 
of JNK-P and relatively moderated increase of MAPK 
Figure 3: CBD treatment did not induce death of neural stem/progenitor cells (NSC/NPC) and astrocytes. (A, B) 
Relative survival of NSC/NPC was determined 16 h after CBD (15 µM) treatment. NSC/NPC was immunostained using anti-SOX2 Ab. 
(C) The typical result of cell cycle-apoptosis analysis demonstrates differential effects of CBD (10 µM) on upregulation of apoptosis in 
U87MG cells and NSC/NPC 72 h after treatment. CBD was dissolved in DMSO; 0.1% DMSO was added to the control cultures as a 
vehicle. Cell cycle-apoptosis analysis was performed using PI staining of DNA and flow cytometry. (D) Radiation-induced (5 Gy) apoptotic 
levels in NSC were not changed after co-treatment with increasing concentration of CBD. Apoptotic levels were determined using PI 
staining of DNA and sub-G1 analysis. (E) Apoptotic levels after combined treatment of immortalized human embryonic astrocytes (IHEA). 
(F, G) Positive effects of CBD (10 µM) on neuronal differentiation of NSC/NPC in cell culture conditions. Induction of differentiation 
was performed for NCS/NPC at low or high density in the presence or absence of CBD. Confocal analysis of immunofluorescent images 
was done using monoclonal Ab against Nestin, an early neuroprogenitor marker (red), and polyclonal Ab against Doublecortin, a neuronal 
marker (green). Bar = 50 μm. Green+yellow/Red cells ratio indicate a degree of neuronal differentiation. Stars indicate a significant 
difference between control and CBD-treated cells.
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p38-P activities were characteristic features of CBD 
treatment in U87MG cells accompanied by pronounced 
increase of phospho-JUN and phospho-ATF2 activities 
(see Figure 1A, 1B and Figure 5B). SP600125 (20 µM, 
an inhibitor of JNK1-3 enzymatic activity specifically 
suppressed phosphorylation of cJUN-P(S73), primary 
target of JNK, as well as ATF2-P(T71), a secondary target 
for JNK. Surprisingly, the vast majority of ATF2-P(T71) 
phosphorylation was controlled by JNK rather than MAPK 
p38 in U87MG cells and was strongly downregulated in 
the presence of SP600125 (Figure 5B). A complicated and 
quite confusing consequence of usage of SB203580 (20 
µM), a specific MAPK p38α/p38β enzymatic inhibitor, 
was a rapid and strong upregulation of the compensatory 
JNK activity and the basal levels of phospho-cJUN and 
phospho-ATF2 by JNK-mediated phosphorylation [51]; 
see Figure 5B. The presence of SB203580 only modestly 
decreased CBD-induced levels of STAT3-Ser727-P (an 
additional target of MAPK p38), compared to control cells 
(Figure 5B).
On the other hand, we observed that SB203580 
(20 µM) protected U87MG cells from CBD-induced cell 
death and efficiently maintained cell-cell interactions and 
the traditional 2D architecture in U87MG culture while 
Figure 4: Upregulation of radiation-induced apoptosis in U87MG and U118MG glioblastoma cells by CBD is dependent 
from CBD pretreatment before irradiation. (A, B) Cell cycle-apoptosis analysis of U87MG and U118MG cells 64 h after indicated 
treatments. The experiments were performed as described in Figure 2C and 2D but with an increased final concentration of CBD (20 µM) 
and dose of γ-irradiation (10 Gy). CBD was added to the cell cultures 30 min before irradiation for panel A or 24 h after irradiation (for 
panel B). Cells were stained with PI, and DNA content in the cell nuclei was determined using the flow cytometry. Effects of small molecule 
inhibitors, SP600125 (20 µM) and SB203580 (20 µM), on CBD-induced (20 µM) apoptosis was detected. The pooled results of four 
independent experiments are presented. Error bars represent means ± S.D. (p < 0.05, Student’s t-test). In panel A, black arrows indicate 
a significant increase in the apoptotic levels of U87MG cells pre-treated by 0–20 µM CBD that followed by γ-irradiation (10 Gy); open 
arrows indicate similar changes in U118MG cells. In panel B, black arrows and open arrows indicate significant differences in radiation-
induced apoptotic levels after treatment by CBD 24 h after irradiation for U87MG and U118MG, respectively. (C) Western blot analysis 
of signaling proteins after treatment of U87MG and U118MG cells by CBD (20 µM) and γ-irradiation (10 Gy), alone or in combination. 
CBD pretreatment was performed 0.5 h before γ-irradiation. (D) Effect of pancaspase inhibitor zVAD-fmk (50 µM) on apoptosis induced 
by combined treatment of CBD (20 µM) and γ-irradiation (10 Gy). Black arrow indicates significant effects of zVAD-fmk on apoptosis in 
U87MG cells, open arrows - in U118MG cells.
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SP600125 (20 µM) demonstrated only partial protection 
(Figure 5C). We further demonstrated that SB203580 (20 
µM) effectively down-regulated apoptosis induced by 
CBD (10–20 µM) in both U87MG and U118MG cells (48 
h after treatment), while SP600125 (20 µM) showed only 
moderate negative effects on CBD-induced apoptosis in 
U87MG cells (Figure 5D, 5E), highlighting a probable 
leading role of MAPK p38-P for regulation of CBD-
induced apoptosis in both glioma cell lines. Interestingly, 
determination of total levels of cell death (by Trypan blue 
staining and light microscopy) showed modest protective 
effect of JNK1/2 inhibition 24–48 h after CBD treatment 
while protective effects of MAPK p38 inhibition were 
well-pronounced at these time points (Figure 5F).
Figure 5: Effects of small molecule inhibitors of cell signaling pathways on modulation of CBD-induced apoptosis in 
U87MG and U118MG glioblastoma cells. (A) Effects of small molecule inhibitor of PI3K, LY294002 (50 µM); IKKβ, BMS345541 
(20 µM); MEK1/2, U0126 (10 µM); and JNK1-3, SP600125 (20 µM) on the corresponding downstream targets were determined using 
Western blot analysis. (B) Effect of small molecule inhibitors of JNK, SP600125 (20 µM), and MAPK p38, SB303580 (20 µM) on their 
targets in U87MG cells. (C) Effects of small molecule inhibitors on CBD-induced cell death. Immunostaining of U87MG cells (48 h after 
treatment) with anti-α-Tubulin mAb was performed. Bar = 50 µm. (D, E) Cell cycle-apoptosis analysis of U87MG and U118MG cells 
48 h after indicated treatments. Cells were stained with PI, and DNA content in the cell nuclei was determined using the flow cytometry. 
Effects of specific molecule inhibitors, BMS345541 (20 µM), LY294002 (50 µM), U0126 (10 µM), SP600125 (20 µM) and SB203580 
(20 µM), on CBD-induced (10–20 µM) apoptosis were detected. The pooled results of four independent experiments are presented. Error 
bars represent means ± S.D. (p < 0.05, Student’s t-test). Stars indicate a significant difference between control (0.2% DMSO) and CBD-
treated glioblastoma cells; open arrows - between CBD (10 µM) and (CBD + inhibitor) treated cells; black arrows indicate a significant 
decrease in the apoptotic levels between CBD (20 µM)- and (CBD + inhibitor)-treated cells. (F) Effects SP600125 (20 µM) and SB203580 
(20 µM) on CBD-induced (10 µM) cell death were determined. The pooled results of four independent experiments are presented. Error 
bars represent means ± S.D. (p < 0.05, Student’s t-test). Open and black circles indicate a significant difference between control (0.2% 
DMSO), CBD-treated and (CBD + inhibitor)-treated cells after 24 h and 48 h, respectively. (G) Effect of small molecule inhibitors of JNK, 
SP600125 (20 µM), and MAPK p38, SB303580 (20 µM) on apoptosis induced by combined treatment of CBD and γ-irradiation (10 Gy). 
The pooled results of four independent experiments are presented. Error bars represent means ± S.D. (p < 0.05, Student’s t-test). Stars and 
arrows indicate a significant increase in apoptotic levels induced by combined treatment in U87MG and U118MG cells, respectively. Black 
circles indicate significant effects of small molecule inhibitors on apoptosis after combined treatment in U87MG cells, open circles - in 
U118MG cells.
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We observed, furthermore, statistically significant 
effects of BMS345541 and LY294002 on upregulation 
of CBD-induced apoptosis (at CBD dose 10 µM but not 
20 µM) in U87MG cells (Figure 5D). U0126 upregulated 
CBD-induced apoptosis in U118MG cells (at the CBD 
dose 20 µM), while additional effects of BMS345541 or 
LY294002 alone on CBD-induced apoptosis in U118MG 
cells were only marginal (Figure 5E). A positive role of the 
EGFR-MEK-ERK pathway in the survival of GBM cells 
and the negative regulation of this pathway by CBD was 
demonstrated in previous publications [26, 47] and were 
further confirmed in the present study by demonstration 
of enhancing effects of U0126 on CBD-induced apoptosis 
in U118MG cells. 
We further assessed effects of a small molecule 
inhibitor of JNK1-3, SP600125 (20 µM), and inhibitor of 
MAPK p38, SB203580 (20 µM), on apoptosis in U87MG 
and U118MG cells after treatment at increased stress 
conditions with CBD (20 µM) and γ-irradiation (10 Gy) 
(Figure 5G). In U87MG and U118MG cells, SB203580 
strongly suppressed the effects of CBD, alone or in 
combination with irradiation, on upregulation of apoptotic 
levels. On the other hand, suppressive effects of SP600128 
on apoptosis after combined treatment in both cell lines 
were significant, even less pronounced than effects of 
SB203580, emphasizing again an important role of MAPK 
p38 for induction of apoptosis after CBD treatment (alone 
or in combination with γ-radiation) and a supplementary 
role for JNK in the enhancement of apoptosis. A cross-talk 
between stress kinases, MAPK p38 and JNK, appears to 
be critical for apoptotic regulation in glioblastoma cells. 
Actually, high level of activation of JNK by CBD could 
initiate JNK-mediated autophagy in glioma cells [52]. 
Cross-talk of autophagy and apoptosis could result either 
in suppression or in upregulation of apoptosis in glioma 
cells, due to unknown regulatory mechanism.
Due to uncertainty of a role for ATF2 as the primer 
MAPK p38-P target in U87MG, we used alternative 
approaches to further elucidate a role of MAPK p38 in 
the regulation of CBD-induced apoptosis: (i) a transient 
transfection of dominant negative p38-ASP construct 
(in the presence of GFP expression vector) that notably 
downregulated active ATF2-P levels in CBD-treated cells 
(Figure 6A); (ii) a transient transfection of dominant-
negative JNK1-ARF + GFP that notably downregulated 
active CBD-induced cJUN-P levels (Figure 6A). An 
efficiency of transfection of U87MG cells (around 
60–70%) is demonstrated on Figure 6B. In parallel 
experiments, we determined the levels of apoptosis (by 
PI staining of apoptotic nuclei and detection of % pre-G1 
cells) among green (GFP-positive) transfected cells using 
flow cytometry. Results obtained in these experiments 
demonstrated a significant downregulation of apoptotic 
levels in transfected cells with deficiency of p38-P 48 h 
after indicated treatments, emphasizing a role of active 
MAPK p38 in the regulation of cell death (Figure 6B). 
A dominant negative p38-ASP construct (Figure 6A, 6B) 
was previously used in our study of melanoma apoptosis 
[53, 54]. Dominant-negative construct JNK1-APF partially 
suppressed cJUN phosphorylation in transfected cells after 
CBD treatment (Figure 6A) and demonstrated a modest 
downregulation of apoptosis after combined treatment of 
U87MG cells (Figure 6B). 
Additionally, we performed a partial silencing 
total p38 levels in U87MG cells using transfection of the 
control and p38 siRNA in the presence of Fluorescein 
Conjugate (at a ratio 5:1) (“Cell Signaling”), see 
Figure 6D, 6E. A down regulation of total p38 and the 
corresponding p38-P levels (6 h after CBD treatment) 
was accompanied by decreased levels of CBD-induced 
apoptosis among transfected green cells (Figure 6E). 
These experiments further confirmed a role for MAPK 
p38 activation in regulation of CBD-induced apoptosis in 
glioblastoma cells. Possible pro-apoptotic targets of p38 in 
glioblastoma cells will be investigated in the subsequent 
experiments of the current study.
A role of NF-κB suppression for an additional 
upregulation of CBD-induced apoptosis in 
glioblastoma cells
NF-κB-mediated gene expression controls 
numerous pro-survival and anti-apoptotic functions in 
normal and cancer cells. On the other hand, expression 
of some pro-apoptotic signaling proteins is also under 
positive control of NF-κB [55–57]. We observed, 
however, that CBD treatment only modestly affected 
high basal levels of active NF-κB p65 in GBM cells 
(see Figure 1A, 1B), suggesting that an additional 
suppression of NF-κB activity by specific inhibitors might 
increase CBD-induced apoptotic levels. NF-κB nuclear 
translocation/activation, as a result of its release from 
the complex with phosphorylated inhibitor IκB after the 
proteasome-dependent degradation of IκB [58], required 
both AKT and IKKβ activities in glioblastoma cells. 
Indeed, substantial suppression of NF-κB p65-P(S536) 
and AKT-P(S473) levels by combined treatment of 
BMS345541 and LY294002 in U87MG cells (Figure 7A) 
induced significant levels of apoptosis in these cells 
determined 16 h after treatment by Annexin-V-FITC and 
PI staining (Figure 7B) or 48 h after treatment determined 
by PI staining of DNA and cell cycle-apoptosis analysis 
(Figure 7C). Combined treatment by these inhibitors in the 
presence of CBD with completely eliminated phospho-
AKT levels and notably reduced NF-κB phospho-p65 
levels (Figure 7A) additionally increased CBD-induced 
apoptosis in U87MG (Figure 7B, 7C), as well as in 
U118MG cells (Figure 7D). Finally, this apoptosis was 
mediated by caspase-3 (due to the characteristic caspase-
3-dependent PARP-1 cleavage; Figure 7A). 
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NF-κB is the crucial regulator of gene expression of 
many pro-inflammatory proteins, such as IL6 and COX2. 
The latter plays a strong anti-apoptotic role for many types 
of cancers, including glioblastoma [59]. CBD treatment 
alone or together with irradiation upregulated protein 
expression levels of COX2 in a number of COX2-positive 
glioblastoma cells (Figure 7E, 7F). Since the COX2 
promoter activity is controlled by NF-κB and AP1 among 
other transcription factors, upregulation of AP1 levels 
(cJUN/ATF2; cJUN/cFOS) appears to increase COX2 
expression following CBD exposure. On the other hand, a 
combination of BMS345541 (10 µM) and LY294002 (50 
µM), which suppressed IKK/AKT-mediated activation 
of NF-κB, further suppressed COX2 protein expression 
(Figure 7E, 7F) in concert with numerous downstream 
targets of these pathways. Total ERK levels were relatively 
stable before and after CBD treatment of U87MG 
cells and were used for normalization of the COX2 
expression levels. NS398 (50 µM), a specific inhibitor 
of the enzymatic activity of COX2, was known to induce 
apoptosis in glioblastomas [59]. A combination of NS398 
with CBD substantially increased levels of apoptosis 
and total cell death induced by CBD (20 µM) alone in 
U87MG cells to levels observed after NF-κB suppression 
(Figure 7G). Taken together, results obtained demonstrated 
a protective role of elevated COX2 expression levels and 
activity, which were induced by CBD in GBM cells, and 
indicated a possible target pathway to further increase 
a proapoptotic activity of CBD. Interestingly, triple 
treatment with CBD, BMS345541 (10 µM) and LY294002 
(50 µM) was not toxic for NSC/NPC but abolished 
stimulating effects of CBD on neuronal differentiation via 
decreasing expression of Doublecortin, a neuronal marker 
(Figure 7H).
Figure 6: Downregulation of ATF-P and cJUN-P levels and silencing MAPK p38 expression: effects on CBD-induced 
apoptosis. (A) Effects of CBD (10 µM; 6 h) on ATF2-P levels in U87MG cells transiently transfected with p38-ASP construct + GFP; 
effects of CBD on cJUN-P levels after transient transfection with dominant-negative JNK-APF + GFP. (B) Efficiency of transfection was 
determined using confocal microscopy for detection GFP in PI-stained nuclei of U87MG cells. (C) In the parallel experiments, the apoptotic 
levels among green U87MG cells transiently transfected by the empty vector + GFP, p38-ASP + GFP or JNK-APF + GFP were determined 
48 h after transfection and 24 h after DMSO or CBD treatment using the flow cytometry. Open arrows indicate a significant decrease in 
CBD-induced apoptosis for p38-ASP transfected cells, black arrows for JNK-ARF-transfected cells. (D) Downregulation of MAPK p38 
expression using p38 siRNA. CBD treatment (additional 6 h) was performed 48 h after transfection. (E) In the parallel experiments, the 
apoptotic levels among green U87MG cells transiently transfected by control siRNA+Green Fluorescein Conjugate and p38 siRNA+Green 
Fluorescein Conjugate were determined 48 h after transfection and 24 h after DMSO or CBD treatment using the flow cytometry. Open 
arrows indicate a significant decrease in CBD-induced apoptosis for p38 siRNA transfected cells.
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Sensitization of glioblastoma to death via death 
receptor-mediated signaling induced by CBD 
Critically important targets of JNK and MAPK 
p38 signaling, transcription factors cJUN, ATF2 and 
CREB in concert with NF-κB, activate expression and 
secretion of proinflammatory cytokines including TNFα 
and IL1β, as well as death ligands TRAIL and FAS Ligand 
[49, 60–63]. In non-treated glioma cells, the extrinsic 
apoptotic pathways are suppressed. Could CBD treatment 
restore and increase extrinsic apoptotic sensitivity in 
glioma cells? Since CBD treatment of glioma cells 
strongly affected JNK pathway, notably MAPK p38 
pathway and maintained relatively high basal NF-κB 
activity, we expected to find CBD-induced upregulation 
of TNFα gene expression. It was a reason first to assess 
Figure 7: Upregulation of CBD-induced apoptosis using combined inhibition of IKK-NF-κB and PI3K-AKT. (A) 
Western blot analysis of signaling proteins in the presence of indicated inhibitors, BMS345541 (20 µM) and LY294002 (50 µM) before 
and after addition of CBD (20 µM) into cell media. (B) The early effects of combined treatment with BMS345541, LY294002 and CBD 
(20 µM) on induction of apoptosis. Annexin-V-FITC and PI staining with the subsequent FACS analysis was performed. Annexin-V-
FITC-positive cells, PI-negative cells are early apoptotic cells while Annexin-V-FITC-positive, PI-positive cells are late apoptotic cells. 
(C, D) Effects of small molecule inhibitors on CBD-induced apoptosis in U87MG (panel C) and in U118MG cells (panel D). Cell cycle-
apoptosis analysis was performed using PI staining and FACS analysis. The pooled results of four independent experiments after indicated 
treatments of glioblastoma cells are demonstrated. Error bars represent means ± S.D. (p < 0.05, Student’s t-test). Stars indicate a significant 
difference between control CBD-treated U87MG cells and (CBD+inhibitors)-treated cells; black circles indicate the significant differences 
for U118MG cells. (E, F) Upregulation of the number of COX2-expressing U87MG cells 6 h after CBD (20 µM) treatment; this effect was 
blocked in the presence of BMS345541 and LY294002. Immunostaining with antibodies to ERK1/2 (green) and COX2 (red) and confocal 
analysis of images were performed. Bar = 50 μm. COX2 levels (normalized to a number of cells) are shown in the panel F. Stars indicate 
a significant difference. (G) Cell cycle-apoptosis analysis was performed 48 h after treatment of U87MG cells by CBD (20 µM) in the 
presence of COX2 enzymatic inhibitor NS398 (50 µM) or BMS345541 (20 µM) and LY294002 (50 µM). Error bars represent means ± S.D. 
(p < 0.05, Student’s t test). Stars indicate a significant difference between CBD-treated glioblastoma cells and these cells after combined 
treatment by (CBD and NS398) or (CBD, BMS345541, and LY294002). (H) A combination of BMS345541 (20 µM) and LY294002 (50 
µM) partially suppressed CBD-induced differentiation of NSC/NPC. Confocal analysis of immunofluorescent images was done using 
monoclonal Ab against Nestin, an early neuroprogenitor marker (red), and polyclonal Ab against Doublecortin, a neuronal marker (green). 
Bar = 50 μm.
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the promoter activity of TNF gene after CBD treatment 
using U87MG cells transiently transfected with the 
luciferase reporter constructs containing the intact TNF 
promoter (-615TNFpr-Luc) and its two variants, either 
with a mutated CRE (-106) site or with a mutated AP1 
(-66) site, which lost ability for binding ATF2-JUN and 
JUN-FOS, respectively, as well as “minimal” -36TNFpr-
Luc (Figure 8A) [64, 65]. CBD treatment substantially 
increased the -615TNF-promoter-directed Luc-reporter 
activity in both U87MG and U118MG lines (about 
3.5-fold). The presence of a mutated CRE site in the 
promoter decreased levels of the basal Luc activity and 
strongly down-regulated CBD-induced Luc activity. 
TNF-promoter-dependent Luc activity notably decreased 
in the presence of the mutated AP1 site. It demonstrated 
a possible role of CBD-induced signaling cascades for 
regulation of TNF gene expression in glioblastoma cells 
(Figure 8A). The human 1.5kbTRAIL promoter contained 
two NF-κB-binding sites, several TRE/CRE sites (that 
could bind different combinations of JUN, FOS, ATF2) 
and GAS site that could bind STAT1/3. These sites and 
the corresponding transcription factors play a critical 
role for TRAIL transcription under normal and stress 
conditions [66–69]. We demonstrated a notable increase 
of the reporter activity for TRAILpr-Luc in U87MG 
cells and modest increase in U118MG cells after CBD 
treatment reflecting a possible role of AP1 activation for 
regulation of the TRAIL promoter activity in glioma cells 
(Figure 8B). 
The real-time qPCR analysis further demonstrated 
a dramatic increase in TNFα mRNA levels 18 h after 
treatment with CBD alone in both glioma lines. In 
U118MG cells, a combination of CBD with γ-irradiation 
additionally increased TNFα mRNA levels, while in 
U87MG cells, downregulation of CBD-induced levels 
by γ-irradiation was observed 18 h after treatment 
(Figure 8C, 8D). Western blot analysis confirmed a 
notable increase in levels of protein expression of TNFα 
in U118MG and TRAIL in U87MG cells after CBD 
treatment (Figure 8E). Secretion of TNFα was also 
substantially increased in both glioblastoma lines after 
CBD treatment with a relatively small positive effect of 
irradiation in combination with CBD for U118MG cells 
(Figure 8F). Relatively minor expression of endogenous 
TRAIL was induced after CBD treatment of U87MG cells 
(Figure 8E).
A remarkable feature of CBD treatment was its 
effect on surface expression of death receptor DR5/
TRAIL-R2 that could be used as an alternative strategy 
for sensitization of glioblastoma cells to external 
apoptotic stimulation. Pretreatment by CBD (20 µM) 
induced significant upregulation of DR5/TRAIL-R2 
surface expression in both U87MG and U118MG cells 
18 h after exposure (Figure 8G). Of note, suppression 
of AKT activity after CBD treatment (see Figure 1B), 
could additionally increase TRAIL-mediated death [70]. 
CBD treatment, furthermore, modestly increased surface 
expression of TNFR1 for both cell lines and TNFR2 for 
U87MG cells, while FAS surface expression was without 
changes or slightly decreased (Figure 8G). 
To assess a role of endogenously produced TNFα 
and TRAIL after CBD treatment of glioblastoma cells, 
we added inhibitory antibody against TNFα (5 μg/ml) 
or against TRAIL into the culture media before CBD 
treatment. Determination of apoptotic levels indicated 
a notable decrease in CBD-induced apoptosis in the 
presence of the inhibitory antibody against TNFα in 
U87MG cells and the absence of effect in U118MG cells 
(Figure 9A, 9B). Furthermore, CBD-induced apoptosis 
was modestly decreased by anti-TRAIL Ab in U87MG 
cells while a decrease in U118MG cells was not significant 
(Figure 9C). Higher levels of the active NF-κB p65-
P(S536) in U118MG cells (Figure 8E) could be one reason 
for resistance of these cells against TNF-induced apoptosis 
[71, 72]. We previously observed the endogenous TRAIL 
secretion by glioma cells in cell cultures [22] that could 
result in TRAIL-mediated apoptosis via an autocrine/
paracrine mechanism in TRAIL-R2/DR5 positive 
glioblastomas with upregulated surface expression of this 
death receptor and suppression of phospho-AKT levels 
after CBD treatment. In contrast, no notable effects on 
CBD-induced apoptosis in both glioma lines was detected 
using an inhibitory anti-FAS-L antibody added to the cell 
media (Figure 9D) correlating with a non-essential role 
of the endogenous FAS-L in regulation of CBD-induced 
death. 
Among three recombinant death ligands, TNFα, 
FasL, and TRAIL, exogenous TRAIL in combination with 
cycloheximide (CHX), 1mg/ml, a classical accelerator of 
apoptosis, induced higher levels of apoptosis in CBD-
pretreated U87MG and U118MG cells (Figure 9E). The 
effective delivery of death ligand TRAIL to glioblastoma 
cells in vivo using NSC as a vehicle with overexpression 
and secretion of TRAIL [73] could probably be used in 
combination with CBD pre-treatment for a further increase 
in efficacy of TRAIL-mediated apoptosis in glioblastoma 
cells.
Regulation of cytokine gene expression by CBD 
alone or in combination with γ-irradiation
Glioblastomas are known as active producers 
of numerous pro-inflammatory cytokines, including 
besides TNFα, cytokines IL1β, IL6 and IL8, and 
growth factors (such as TGFβ) that affect via paracrine/
autocrine signaling the cancer cells themselves and 
actively participate in intercellular communication with 
cancer microenvironment including tumor infiltrating 
lymphocytes [74]. We examined effects of CBD and 
γ-irradiation, alone or in combination, on gene expression 
of these cytokines in U87MG and U118 cells using 
real-time qPCR (Figure 10). CBD (20 µM) alone and, 
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Figure 8: Effects of CBD on TNFα and TRAIL expression and secretion and surface expression of death receptors in 
glioblastoma cells. (A) Effects of CBD (20 µM) on TNF-promoter-luciferase reporter activity in transiently transfected glioblastoma 
cells. “Minimal” -36TNFpr-Luc, -615TNFpr-Luc (wt) and two mutated constructs, -615TNFpr(mutCRE)-Luc and -615TNFpr(mutAP1)-
Luc were used. The pooled results of three independent experiments are presented in panel A. Error bars represent means ± S.D. (p < 0.05, 
Student’s t-test). Stars and black circles indicate a significant difference in the TNF promoter activity after CBD treatment in U87MG 
and U118MG cells, respectively. (B) Effects of CBD (20 µM) for 6 h on TRAIL-promoter-luciferase activity in transiently transfected 
glioblastoma cells, 24 h after transfection. (C, D) Quantitative real-time PCR analysis of the kinetics of TNFα mRNA levels after treatments 
of U87MG and U118MG cells by CBD (20 µM) and γ-irradiation (5 Gy) alone or in combination. The graphs indicate the fold change of 
target gene mRNA levels against time-point control after normalized to reference gene (beta-Actin). The pooled results of four independent 
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experiments are presented in panel B. Error bars represent means + S.D. (p < 0.05, Student’s t-test). Stars indicate a significant difference 
in mRNA levels between control and CBD-pretreated cells, black circles - between irradiated (5 Gy) and irradiated in the presence of CBD 
(20 µM) cells. (E) Western blot assay of active and total NF-κB p65, TNFα p17 and TRAIL p32 levels 6 h after treatment by CBD in glioma 
cells. (F) TNFα protein levels secreted into the media after indicated treatments of glioblastoma cells were detected by ELISA. (G) Effects 
of CBD treatment on surface expression of death receptors in U87MG and U118MG glioblastoma cells. Surface expression of the main 
death receptors DR5/TRAIL-R2, FAS, TNFR1 and TNFR2 in U87MG and U118MG cells was determined by immunostaining and the 
flow cytometry. Cells were treated overnight in presence of 0.1% DMSO (green lines) or 20 µM CBD (red lines); ns–non-specific staining.
Figure 9: Modulation of apoptosis in glioblastoma cells. (A–D) Effects of anti-TNF inhibitory antibody (5 μg/ml), anti-TRAIL 
inhibitory antibody (5 μg/ml) or anti-Fas-L inhibitory antibody (5 μg/ml) in the media on CBD-induced apoptosis in U87MG and U118MG 
cells. Typical experiment of cell cycle apoptosis-analysis with PI-stained nuclei is shown in the panel B. The pooled results of four 
independent experiments are presented in panels (A–C). Error bars represent means ± S.D. (p < 0.05, Student’s t-test). Stars indicate a 
significant difference in CBD-induced apoptotic levels between control and anti-TNF- or anti-TRAIL-treated U87MG cells. (E) Effects of 
CBD (20 µM) pretreatment (18 h) on the subsequent treatment (24 h) of glioma cells with exogenous FasL (50 ng/ml) + CHX (1 µg/ml), 
TNFα (20 ng/ml) + CHX, and TRAIL (50 ng/ml) + CHX. Levels of apoptosis were determined using cell cycle-apoptosis analysis. Stars 
and black circles indicated significant differences.
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especially, in combination with γ-irradiation (5 Gy), 
induced a strong increase IL1β and IL6 after combined 
treatment (4 h and 18 h, respectively) in U118MG 
cells and less pronounced changes in U87MG cells, a 
substantial increase in gene expression of IL8 in both 
cell lines (Figure 10A); and minor changes in already 
high TGFβ levels in both lines (data not shown). Protein 
secretion of IL6 into the culture media was correlated 
with level of gene expression (Figure 10B). Hence, CBD 
in combination with γ-irradiation, via regulation of pro-
inflammatory signaling in glioblastoma could affect a 
balance between survival and death of cancer cells in stress 
conditions. We suggested that prolonged expression of a 
high level of IL6 after combined treatment of U118MG 
cells might result in decreased levels of apoptosis in 
these cells. Indeed, addition of anti-IL6 inhibitory Ab 
(5 µg/ml) to the cell media significantly increased levels of 
apoptosis in glioma cells after treatment with CBD alone 
or in combination with γ-irradiation (Figure 10C). 
Effects of antagonists of CB1 and CB2 receptors 
on CBD-mediated signaling cascades in 
glioblastoma lines
U87MG and U118MG glioblastoma cells exhibit 
high protein expression of cannabinoid receptors, CB1 
and CB2 (Figure 11A, 11C) and a well pronounced 
dose-dependent apoptotic response to CBD treatment. 
In contrast to ∆THC and endocannabinoids, CBD only 
slightly interacts with CB1 and CB2 receptors but after 
penetration into glioma cells it induced oxidative stress 
[40, 75]. 
The problem of CB1/2 receptor interfering with 
CBD-mediated signaling is not still completely resolved. 
In spite of suggestion about CB1/2 independent or 
almost independent mechanism of CBD signaling, 
mutual interference between CB1/2 receptor- and CBD 
signaling was observed [48, 76, 77]. Based on this 
suggestion, we evaluated possible downstream effects 
of the antagonists of CB1- or CB2-receptor signaling on 
CBD-mediated signaling cascades in glioblastomas. For 
this purpose, CBD (20 µM) was used alone or together 
with a CB1 receptor antagonist (inverse agonist) AM251 
(20 µM) or with a CB2 receptor antagonist (inverse 
agonist) SR144528 (20 µM) (Figure 11) in U87MG and 
U118MG cells for 4h exposure. AM251 diluted in DMSO 
was added to cell cultures 15 min before CBD. DMSO 
(at final concentration 0.2%) was used as a vehicle. We 
observed moderate variations of the high basal levels of 
phospho-p65 NF-κB, phospho-AKT and phospho-ERK1/2 
4 h after CBD treatment detected in both glioblastoma 
lines; these active levels were insensitive to co-treatment 
with AM251 (Figure 11A). Furthermore, CBD-mediated 
increase in phospho-MAPK p38 levels, as well as 
upregulation of phospho-ATF2 levels were not notably 
affected by AM251 in U87MG and U118MG cells. The 
most remarkable effect of AM251 was suppression of 
CBD-induced of JNK1/2 phosphorylation in U87MG 
(Figure 11A). It could also be observed in U118MG 
cells after prolonged exposure of X-ray film during ECL 
(Figure 11A). Upregulation of phospho-(Ser73)-cJUN 
level by CBD was partially suppressed in the presence 
of AM251 in U87MG cells; it was well correlated with 
phospho-JNK1/2 levels in U87MG cells (Figure 11A). 
Due to a deficiency of active JNK1/2 in U118MG cells, 
cJUN could be additionally phosphorylated by a different 
kinase, such as ERK1/2, and was not decreased by AM251 
in these cells. Hence, AM251 effectively suppressed CBD-
induced JNK1/2 activation in U87MG and partially in 
U118MG cells in concert with relatively minor effects 
on several signaling pathways. These effects of AM251 
may reflect prevention of oxidative stress, which could be 
induced by CBD treatment. 
Next, we addressed a question regarding probable 
effects of AM251 on CBD-induced apoptosis. Quite 
surprisingly, AM251 (20 µM) more efficiently suppressed 
CBD-induced apoptosis in U118MG compared to U87MG 
cells 72 h after treatment (Figure 11B). Data obtained were 
correlated with a minor proapoptotic role for JNK-cJUN in 
CBD-induced apoptosis but did not reveal critical targets 
for AM251-dependent anti-apoptotic activity in several 
signaling pathways in glioblastoma cells. Immunostaining 
with Ab to total ERK and fluorescent microscopy also 
demonstrated a non-effective protection of AM251 against 
CBD-induced U87MG cell death (data not shown).
On the other hand, a combination of CBD and 
SR144528 (20 µM), an antagonist (inverse agonist) of 
CB2 receptor, did not demonstrate notable effects on NF-
κB p65-P, ERK-P, AKT-P (data not shown) and MAPK 
p38-P levels in U87MG and U118MG cells (Figure 11C). 
The prominent effect of SR144528 in combination with 
CBD was again a suppression of CBD-induced activation 
of JNK1/2 in U87MG cells (Figure 11C). This effect 
was only modestly pronounced in U118MG cells and 
could be detected after prolonged exposure of X-ray film 
during ECL. It was accompanied by the corresponding 
downregulation in CBD-induced phospho-cJUN levels in 
U87MG cells but not in U118MG cells (Figure 11C). 
SR144528 effectively decreased CBD-induced 
apoptosis at relatively early phase that was detected with 
Annexin-V-FITC and PI staining in both GBM lines 
16 h after treatment (data not shown) and substantially 
downregulated total apoptotic (the sub-G1) levels 72 h 
after treatment determined by cell cycle and apoptosis 
analysis using PI-staining DNA and the flow cytometry 
(Figure 11D). We also observed, using the phase contrast 
microscopy and immunostaining for ERK-positive cells, 
that the presence of SR144528 in the culture media 
substantially reduced CBD-induced damage in the GBM 
cell cultures and decreased the levels of GBM cell death 
(Figure 11E, 11F). The similar protective effects of 
SR144528 were observed in CBD-treated U87MG cells 
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Figure 10: Cytokine gene expression in glioblastoma cells determined by quantitative real-time PCR. (A) Quantitative 
real-time PCR analysis of IL1β, IL6 and IL8 mRNA levels after treatments of U87MG and U118MG cells by CBD (20 µM) and γ-irradiation 
(5 Gy) alone or in combination. The graphs indicate the fold change of target gene mRNA levels against time-point control after normalized 
to reference gene (beta-Actin). The pooled results of four independent experiments are presented. Error bars represent means ± S.D. 
(p < 0.05, Student’s t-test). Stars indicate a significant difference in mRNA levels between control and CBD-pretreated cells, black circles - 
between irradiated (5 Gy) and irradiated in the presence of CBD (20 µM) cells. (B) IL6 protein levels secreted into the media after indicated 
treatments of glioblastoma cells were detected by ELISA. Black circles indicate significant differences in IL6 secretion after treatment of 
U118MG cells CBD (20 µM) alone or in combination with irradiation (5 Gy). (C) Effects of anti-IL6 inhibitory antibody (5 μg/ml) in the 
media on apoptosis induced by CBD (20 µM) alone or combined treatment of CBD and γ-irradiation of U87MG cells. Black circles indicate 
a significant upregulation of apoptosis after combined treatment of U118MG cells in the presence of anti-IL6 Ab.
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(data not shown). In general, signaling effects of CB1 and 
CB2 receptor antagonists appear to be strongly linked with 
effects on CBD-induced oxidative stress. Furthermore, 
our observations indicated on more efficient suppression 
of CBD-induced apoptosis by antagonist of CB2 receptor 
signaling, compared to AM251, in glioblastoma cells. A 
similar effect of a CB2 receptor antagonist on suppression 
of CBD-induced apoptosis in glioblastoma cells was 
previously observed [48]. 
To further extend our study, we elucidated effects 
of CB1/2 receptor antagonists on CBD-induced apoptosis 
in the T98G human glioblastoma line, which was also 
CB1- and CB2-receptor positive and contained mutated 
p53 and PTEN (Figure 12). The presence of AM251 
or SR144528 did not significantly affect the basal or 
CBD-mediated AKT-P and NF-κB-P levels in T98G 
cells. There was also a tendency for downregulation of 
ERK-P 4 h after CBD treatment that was not restored 
after co-treatment with AM251 and SR144528. The basal 
levels of MAPK p38-P were high and CBD alone might 
have a moderate negative effect on p38-P level in T98G 
cells (Figure 12B). A dramatic upregulation JNK1/2-P 
Figure 11: Effects of cannabidiol (CBD) alone or in combination with (i) AM251, an antagonist of CB1-receptor 
mediated signaling cascades, (ii) SR144528, an antagonist of CB2-receptor mediated signaling cascades, on main 
signaling pathways and apoptosis in U87MG and U118MG glioblastoma cell lines. (A) Effects of AM251 (20 µM), on 
CBD-induced (20 µM) changes in main signaling pathways were determined in glioblastoma cell lines using Western blot analysis. 
JNK-P detection is shown on two subpanels with normal (for U87MG) and prolonged exposure (for U118MG) of X-ray film during 
ECL. Quantitative densitometry of protein bands was performed. (B) Effects of AM251 (20 µM), on CBD-induced (20 µM) apoptosis 
in glioblastoma lines. Vehicle contains 0.2% DMSO. Cell cycle-apoptosis analysis was performed using PI staining DNA and the flow 
cytometry. The pooled results of four independent experiments are presented on the upper panel. Error bars represent means ± S.D. (p < 
0.05, Student’s t-test). Stars indicate a significant difference between (CBD+Vehicle)- and (CBD+AM251)-treated U87MG cells; double 
stars -- between (CBD+Vehicle)- and (CBD+AM251)-treated U118MG cells. (C) Effects of SR144528 (20 µM), on CBD-induced (20 µM) 
changes in main signaling pathways were determined in glioblastoma cell lines using Western blot analysis. Quantitative densitometry of 
protein bands was performed. (D) Effects of SR144528 (20 µM), on CBD-induced (20 µM) apoptosis was determined 72 h after treatment. 
(E) Phase-contrast microscopy of U87MG cells 64 h after indicated treatment: control, DMSO 0.2%; CBD 20 µM; SR144528 20 µM; 
and combination of (CBD+SR144528). Typical images are shown. (F) Immunostaining total ERK (green) and fluorescent microscopy of 
U87MG cells 64 h after indicated treatment. Typical images are shown. Bar = 50 μm.
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activity accompanied by increased phosphorylation 
of its major downstream target, cJUN, was also a 
characteristic feature of CBD treatment in this line that 
was efficiently suppressed by SR144528 co-treatment 
and less efficiently by AM251 (Figure 12A, 12B). 
Apoptotic effects of CBD were well pronounced in 
T98G cells using both the detection with Annexin-V-
FITC + PI 16 h after treatment (Figure 12C) and cell 
cycle-apoptosis analysis 72 h after treatment. AM251 
and, especially SR144528, effectively suppressed the 
apoptotic commitment (Figure 12D).
In general, we demonstrated cell-specific 
quantitative differences in CBD-induced regulation of 
some major signaling proteins in U87MG, U118MG and 
T89G glioblastoma lines. A downstream cross-talk of CBD 
signaling (such as upregulation of phospho-JNK) with 
antagonists of CB1- and CB2-dependent signaling resulted 
in suppression of this upregulation in two glioblastoma 
lines. This quite remarkable phenomenon, which had 
only a moderate effect on CBD-induced apoptosis, needs 
an additional investigation, as well as elucidation of 
additional targets that protect glioma cells against CBD-
induced apoptosis. Interestingly, combined activation of 
CBD-signaling and ∆THC-CB1/2 dependent signaling 
exhibited synergistic effects and induced high levels of 
apoptosis in glioblastomas [29, 47]. Accelerating effects of 
γ-irradiation on CBD-induced apoptosis were observed in 
the present study for three glioblastoma lines (Figure 13A). 
Figure 12: Effects of cannabidiol (CBD) alone or in combination with (i) AM251, an antagonist of CB1-receptor 
mediated signaling cascades, (ii) SR144528, an antagonist of CB2-receptor mediated signaling cascades, on main 
signaling pathways and apoptosis in T98G glioblastoma cell lines. (A, B) Effects of AM251 (20 µM) or SR144528 (20 µM) on 
CBD-induced (20 µM) changes in main signaling pathways were determined in T98G cells Western blot analysis. Quantitative densitometry 
of protein bands was performed. (C) Effects of SR144528 (20 µM), on CBD-induced (20 µM) apoptosis 16 h after treatment. Vehicle 
contains 0.2% DMSO. Annexin-V-FITC and PI staining was performed and followed by FACS analysis. (D) Effects of AM251 (20 µM) or 
SR144528 (20 µM) on CBD-induced (20 µM) apoptosis in T98G cells. Vehicle contains 0.2% DMSO. Cell cycle-apoptosis analysis was 
performed using PI staining DNA and the flow cytometry. The pooled results of four independent experiments are presented on the upper 
panel. Error bars represent means ± S.D. (p < 0.05, Student’s t-test). Open arrows indicate a significant difference between (CBD+Vehicle), 
(CBD+AM251)- and (CBD+SR144528)-treated T98G cells.
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On the other hand, lipid-soluble antioxidant, such as 
vitamin E, might partially inhibit CBD-induced oxidative 
stress and apoptosis or total cell death in glioblastoma 
cells (Figure 13A and 13B). Activation of both JNK and 
MAPK p38 and their downstream targets, such as TRAIL 
and its receptor TRAIL-R2, seems especially important for 
mediation of CBD-induced apoptosis in gliomas through 
the external apoptotic signaling mechanism. 
Figure 13: Effects of cannabinoids and γ-irradiation on cell signaling pathways and regulation of apoptosis in glioblastoma 
cells. (A) Dose-dependent effects of CBD alone, in combination with VitE (50 µM), or in combination with γ-irradiation (10 Gy) on apoptosis 
of human glioblastoma cells, which was determined by PI staining DNA and the flow cytometry. The pooled results of four independent 
experiments are presented on the upper panel. Error bars represent means + S.D. (p < 0.05, Student’s t-test). Stars, open arrows and black 
arrows indicate significant differences between CBD-treated and (CBD+10Gy) treated U87MG, U118MG and T98G cells, respectively. (B) 
CBD-induced cell death was partially suppressed in the presence of SR144528 (20 µM), a CB2 receptor antagonist, or Vitamin E. U87MG cells 
were immunostained using anti-β-tubulin monoclonal Ab. Bar = 50 µm. (C) Regulation of signaling pathways and apoptosis in the presence 
of cannabinoids. ∆THC and endocannabinoids (eCB) induce signaling cascades through CB1 and CB2 receptors. ∆THC could also affect 
growth factor receptors (GFR) signaling. CB1/2 receptors coupling to Gi signaling assemble is associated with activation of RAF-MEK-ERK 
pathway in the normal neural and glial cells, as well as in glioma cells. Activation of the PI3K/Akt-mTORC1 pathway by GFR with tyrosine 
kinase activity (RTK) might be negatively affected by CB1 receptor-dependent activation of ERK. RTK signaling activates also JAK/STAT3 
pathway. ∆THC-induced activation of CB1 and CB2 receptors upregulates ceramide synthesis in the endoplasmic reticulum (ER) and induces 
ER-stress, which suppresses/ downregulates RTK-induced AKT and ERK activation in glioma cells. It further suppresses mammalian target of 
rapamycin complex-1 (mTORC1) activity accompanied by suppression of the general translation but upregulation of autophagy. In contrast, 
cannabidiol (CBD) may directly penetrate into the cells without binding CB1/2 receptors. In the cells, CBD dramatically upregulates ROS 
production and ROS-dependent network, including activation of JNK. MAPK p38 could be activated by CBD in both ROS-dependent and 
ROS-independent mechanisms. These signaling pathways further regulate mitophagy, autophagy and the mitochondrial apoptotic pathway in 
glioblastoma cells, synergizing with γ-irradiation-induced cell death. CB1/2 receptors still could control CBD-induced signaling. TNFα /TNFR1 
signaling might play a dual role via regulation of both survival functions (via NF-κB) and apoptotic or necroptotic functions. CBD treatment in 
combination with γ-radiation strongly affects TNF and TNF-R1 expression with the subsequent induction of proinflammatory cytokine (IL6 and 
IL8) expression and secretion. CBD could upregulate production of TRAIL and surface expression of TRAIL-R2 restoring external apoptotic 
signaling in glioblastoma cells.
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DISCUSSION
The mechanism of natural surveillance and killing 
of cancer cells based on the enhancement of the immune 
response has been successfully used in immunotherapy, 
due to the introduction of the immune checkpoint 
inhibitors [78–80]. There are, however, significant 
problems to effectively apply immunotherapy for brain 
tumor treatment, due to the blood-brain barrier. An 
alternative and complementary possibility for cancer 
treatment is an intensive elucidation of cell signaling 
receptors, which regulate signal-dependent gene 
expression and are present at increased levels in cancer 
cells. CB1 is the most abundant cell surface receptor in the 
brain; CB2 receptor is also widely expressed on glial cells 
[77]. Both receptors by binding endocannabinoids activate 
signaling cascades, which control proliferation, survival 
and other normal functions.
Numerous investigations highlighted a surprising 
role for cannabinoids in brain tumors: ∆THC via activation 
of the corresponding CB1 and CB2 receptors could induce 
cell death in human glioblastoma and in some other types 
of cancer [28, 32, 39]. We have focused for this study on 
the signaling pathways that could regulate killing effects 
of cannabidiol (CBD), a non-toxic cannabinoid without 
psychogenic activity and with low affinity for CB1 and 
CB2 receptors. In spite of CB1/2-receptor independent 
initiation of CBD signaling pathways, there was a 
downstream cross-talk of these signaling pathways with 
CB1/CB2-mediated signaling, as we demonstrated in the 
present study using specific antagonists (inverse agonists) 
of CB1- and CB2 receptors. 
Characteristic features of CBD-induced signaling 
in glioblastomas represent the consequences of oxidative 
stress [40] and include the early induction/ upregulation of 
JNK-cJUN and modulation of MAPK p38-ATF2 signaling 
pathways and the late downregulation of the levels of an 
active phosphorylated form of AKT and ERK involved in 
regulation of cell proliferation and survival (Figure 13C). 
In general, strong suppression of AKT1-mTOR and a 
partial suppression of ERK pathways, in concert with 
substantial upregulation of JNK activation, the high basal 
or induced MAPK p38 activity, and very active p53-
BAX, may promote autophagy/apoptotic commitment in 
glioblastoma cells, as was previously investigated [39, 41, 
81, 82]. Taken together, these changes in cell signaling 
dramatically misbalanced the regulation of autophagy, cell 
survival, and death [52] (see Figure 13C). An important 
observation previously reported for normal young and 
mature astrocytes and confirmed in our investigation for 
NSC/NPC was the absence of pro-apoptotic signaling by 
CBD in normal neural cells [32, 39].
We demonstrated three additional approaches to 
further increase killing efficiency of CBD in glioblastomas. 
The first quite traditional approach was based on a general 
suppression of PI3K-AKT and IKK-NF-κB signaling 
pathways. A universal role of upregulation of PI3K-
AKT and IKK-NF-κB signaling pathways in cancer cells 
(based on both genetic and epigenetic mechanisms) has 
been well established in many types of tumors, including 
glioblastoma. It also increased resistance against the lethal 
effects of radiation, chemotherapy or oxidative stress 
[83, 84]. Consequently, suppression of PI3K-AKT and 
NF-κB signaling pathways was used for sensitization of 
human glioblastomas to chemotherapy or death-receptor 
mediated apoptosis [70, 85, 86]. CBD treatment that was 
accompanied by the late inhibition of AKT pathway did not 
notably decrease NF-κB activity. Combined treatment with 
small molecule inhibitors of IKKβ and PI3K-AKT that was 
necessary for additional suppression of NF-κB activation 
substantially increased CBD-induced apoptosis in three 
glioblastoma lines, as observed in the current study.
An MAP3K, ASK1, was active in glioblastoma lines 
used in the present study (our non-published data) and 
could be further upregulated by different types of stress 
including oxidative stress, endoplasmic reticulum (ER) 
stress, and calcium influx [87, 88]. Since cannabinoids 
are involved in the initiation of both oxidative stress [40] 
and ER stress [44] in glioblastoma, they could possibly 
target ASK1 activity (modulating its phosphorylation, the 
subsequent activation, and final degradation) and then its 
downstream targets, MAPK p38 and JNK. Upregulation of 
ASK1 activity in U87MG cells after CBD treatment and 
γ-irradiation could possibly be correlated with downstream 
p38-ATF2 and JNK activation. This challenging problem 
for a potential role of ASK1 in CBD-induced signaling in 
glioblastoma cells needs additional investigation.
The second approach was based on a combination of 
CBD treatment and subsequent γ-irradiation resulting in the 
effective induction of apoptosis in three glioblastoma lines 
using relatively high doses of γ-irradiation and CBD. The 
current external beam radiation therapy of glioblastoma at 
very high doses (56–60 Gy) alone or in combination with 
chemotherapy results in the mitotic catastrophe, arresting 
cell proliferation and, finally, in necrotic death of tumor 
cells, as well as of targeted normal cells in the areas of 
treatment. A possibility to decrease radiation doses in 
the presence of alternative inducers of cell death, such as 
CBD and ∆THC, alone or especially in combination looks 
as a promising alternative to the standard glioblastoma 
treatment, based on the recent animal experiments with 
the triple combination, CBD, ∆THC and γ-irradiation 
[29]. Interesting one aspect of combined treatment by 
CBD and γ-irradiation was the order of the treatment: first 
CBD then irradiation; delay of CBD treatment decreased 
apoptosis. Kinetics of CBD-induced expression and 
secretion of cytokines (both prosurvival and proapoptotic) 
appears to significantly affect cell death regulation and 
synergy between CBD and irradiation. So, suppression of 
CBD-induced IL6 autocrine/paracrine stimulation of the 
protective signaling (Figure 10C) might be involved in 
upregulation of apoptosis induced by combined treatment.
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The third approach for sensitization of glioblastoma 
cells to death via increased surface expression of death 
receptors including TNF receptors and TRAIL-R2/DR5 
based on the corresponding actions of CBD was also 
demonstrated in the current study (see Figures 8 and 9). 
Interestingly, CBD-induced down-regulation of AKT and 
ERK1/2 activities may result in down-regulation of FOXO3A 
phosphorylation and upregulation of its nuclear translocation/ 
nuclear function that further upregulated the endogenous 
TRAIL expression, probably, in concert with AP1, ATF2 
and NF-κB. We indeed observed a CBD-induced increase 
of TRAIL protein levels in U87MG glioblastoma cells 
(Figure 1B and 8E). Such a regulatory mechanism was also 
described for TIC10, a pro-apoptotic small molecule inducer, 
which was found after an intensive screening of the chemical 
libraries [89]. Furthermore, TIC10 could trigger cytotoxicity 
in solid tumor cells by inducing a stress response [90]. 
Multiple cytokine gene expression and secretion 
induced by combination of CBD and γ-irradiation, as we 
observed in the present study, additionally complicated a 
roadmap of signaling events in glioblastomas. There is a 
direct connection between TGFβ, IL6-STAT3, IL1β-NF-
κB, TNFα-NF-κB and JNK-AP1 pathways and COX2 
gene expression, PGE2 production and regulation of 
stability of exogenous cannabinoids and endocannabinoids 
[91–93]. We found in the present study an additional 
functional combination of irradiation and CBD-dependent 
modulation of cell signaling pathways that further permit 
an increase of efficiency of glioblastoma treatment with 
some radioprotective effect for NSC/NPC and, probably, 
for neurons. Since COX2 oxygenates and inactivates both 
exogenous and endogenous cannabinoids, we suggested 
that suppression of COX2 activity by a specific enzymatic 
inhibitor [59] could substantially activate of cannabinoid 
signaling cascades [92] and cannabidiol-induced 
apoptosis. We indeed observed such enhanced CBD-
induced apoptosis in the present study (see Figure 7). 
In general, our study provides additional possibilities to 
enhance clinical usage of cannabidiol for brain cancer 
treatment and indicate the molecular targets for further 
improving efficiency of treatment. 
MATERIALS AND METHODS
Reagents
PI3K inhibitor LY294002, IKK inhibitor 
BMS345541, MEK inhibitor U0126, MAPK p38 inhibitor 
SB203580 and JNK inhibitor SP600125 were purchased 
from Calbiochem (La Jolla, CA, USA). Human soluble 
Enzo Killer-TRAIL (recombinant #ALX-201-073-C020), 
Super-Fas-Ligand (recombinant; #ALX-522-020) and anti-
human TRAIL Ab (#ALX-210-732) were purchased from 
Enzo Life Sciences (San Diego, CA, USA). Recombinant 
human TNFα (#210-TA-010) and anti-human TNFα mAb 
(#MAB610-100) were obtained from R&D Systems 
(Minneapolis, MN). Anti-human IL6 mAb (#MAB2061R) 
were purchased from R&D Systems (Minneapolis, MN). 
Cannabidiol (exempt preparation; #90081); AM251 
(#71670); SR144528 (#192703-06-3) and NS398 (#70590) 
were obtained from Cayman Chemical (Ann Arbor, MI).
Human embryonic neural stem cells (NSC) in 
culture
Cryopreserved human embryonic neural stem cells 
(NSC) were obtained from Gibco/Life Technologies 
(Carlsbad, CA, USA) as a commercially available product 
(N7800-200). The cells were derived from NIH approved H9 
(WA09) human embryonic stem cells. The cells were plated 
in 6-well culture plates coated with fibronectin and incubated 
at 37°C in complete growth medium NSC/SFM, which 
contained serum-free DMEM/F12 supplemented with 2 mM 
GlutaMAX, bFGF (20 ng/ml), EGF (20 ng/ml) and StemPRO 
neural supplement (2%). All reagents were obtained from 
Gibco/Life Technologies (Carlsbad, CA, USA).
Neural stem cells were plated on polyornithine- and 
laminin-coated 6-well plates, which contained similarly 
coated cover slips, in complete NSC/SFM. After 2 
days, neuronal differentiation was initiated by neuronal 
differentiation media, which contains Neurobasal medium, 
B-27 Serum-free supplement (2%) and 2 mM GlutaMAX 
(Gibco/Life Technologies). The medium was changed 
every two days. A neuronal phenotype was confirmed 
using immunofluorescence detection 8–10 days after 
initiation of differentiation. 
Glioblastoma cell lines
Three human glioblastoma lines, which were used in 
the present study, were obtained from the ATCC: i) U87MG 
(HTB-14): very tumorigenic, highly invasive, highly 
rearranged hypodiploid with several hundred mutations, 
TP53wt, PTENmut; ii) U118MG (HTB-15): tumorigenic, 
moderate invasive; genome average copy number 2.2, 
several hundred mutations, TP53mut, PTENmut iii) T98G 
(CRL-1690): non-tumorigenic; moderate invasive, highly 
rearranged hypopentaploid/ hypohexaploid, several hundred 
mutations, TP53mut, PTENmut) [85, 94]. There are some 
contradictions about the origin and maintenance of the 
U87MG (HTB-14) glioma cell line in the ATCC [95]; 
however, they do not interfere the results of the present 
study (http://cansar.icr.ac.uk/cansar/search_results/158086/; 
https://portals.broadinstitute.org/ccle_legacy/home). All 
glioblastoma lines were cultured as described in DMEM 
with 10% FBS and 1% pyruvate [96]. 
Immunocytochemistry analysis 
Cells were fixed with 4% paraformaldehyde in PBS 
for 60 min. Immunochemical staining was performed 
using standard protocols. NSC/NPC and young neurons 
were stained for the undifferentiated NSC marker, Nestin 
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(using mAb #MAB5326 from Millipore, Temecula, CA, 
USA) and for the neuronal marker, Doublecortin (using 
Ab #4604 from Cell Signaling, Danvers, MA, USA). 
Glioblastoma cells were stained for ERK1/2 (Ab #9102 
from Cell Signaling), COX2 (mAb #160112 from Cayman 
Chemical) and α-Tubulin (mAb #T5168 from “Sigma”). 
The secondary Abs were Alexa Fluor 594 goat anti-
mouse IgG and Alexa Fluor 488 goat anti-rabbit IgG 
from Molecular Probes/Life Technologies (Carlsbad, CA, 
USA). A laser scanning confocal microscope (Nikon TE 
2000 with EZ-C1 software, Tokyo, Japan) was used for 
immunofluorescence image analysis. 
Irradiation procedures
To determine sensitivity to γ-rays, plated NSC, 
astrocytes and glioblastoma cells were exposed to radiation 
from a Gammacell 40 137Cs irradiator (dose rate, 0.82 Gy/
min) at Columbia University. Six to 48 h after irradiation, 
cells were stained with PI and analyzed by flow cytometry 
for cell cycle-apoptosis studies. 
FACS analysis of TRAIL-R2/DR5, TRAIL-R1/
DR4, FAS and TNF-R levels 
Surface levels of TRAIL-R2/DR5 (PE anti-human 
DR5 Ab, eBioscience #12-9908), TRAIL-R1/DR4 (PE 
anti-human DR4, eBioscience #12-6644); FAS/CD95 
(PE anti-human CD95 mAb, BD Pharmingen #555674) , 
TNF-R1 (PE anti-human TNFR1 mAb, R&D #FAB225P) 
and TNF-R2 (PE Rat anti-human CD120b #552418, 
BD Pharmingen) on human glioblastoma cell lines were 
determined by staining with the corresponding Abs 
and subsequent flow cytometry. A FACS Calibur flow 
cytometer (Becton Dickinson, Mountain View, CA, USA) 
and the CellQuest program were used to perform flow 
cytometric analysis. All experiments were independently 
repeated 3–5 times. 
Cell death studies 
For induction of apoptosis, cells were exposed 
to cannabidiol and to γ-irradiation (5–10 Gy) alone or 
in combination. In some experiments, small molecule 
inhibitors of cell signaling pathways were additionally 
used. Furthermore, apoptosis was induced TRAIL, TNFα, 
FasL, and CHX alone or in combination. Apoptosis 
levels (% of apoptotic nuclei) in cells after fixation 
and permeabilization by 70% ethanol were assessed 
by propidium iodide (PI) staining and quantifying 
the percentage of hypodiploid nuclei (pre-G1) using 
FACS analysis. Alternatively, staining of fresh cells by 
Annexin-V-FITC + PI and quantifying the percentage of 
Annexin-V-FITC-positive, PI-negative cells (the early 
apoptotic), Annexin-V-FITC-positive, PI-positive cells 
(the late apoptotic) and Annexin-V-FITC-negative, PI-
positive cells (the secondary necrotic) was performed 
using reagents from BD Pharmingen ( San Diego, CA) 
that was followed by the flow cytometry on FACS Calibur 
flow cytometer (Becton Dickinson) using the CellQuest 
program. Additionally, Trypan blue exclusion test was 
used for determination of cell viability and total death 
levels. Clonogenic survival assay of glioblastoma cells 
before and after treatment with increased doses of CBD 
and γ-radiation in the presence or absence of a PI3K-AKT 
inhibitor LY294002 (40 µM), an IKK-NF-κB inhibitor 
BMS345541 (10 µM) or several other small molecule 
inhibitors was also performed using a standard method. 
Western blot analysis 
Total cell lysates (50 µg protein) were resolved 
on SDS-PAGE, and processed according to standard 
protocols. The antibodies used for Western blotting 
included anti-β-Actin mouse mAb (Sigma, St. Louis, MO, 
USA).The antibodies to human antigens obtained from 
Cell Signaling (Danvers, MA) included phospho-p44/
p42 MAPK (Erk1/2) (T202/Y204) rabbit mAb #4377; 
p44/p42 MAPK (Erk1/2) Ab #9102; phospho-SAPK/
JNK (Thr183/Tyr185) rabbit mAb #4668; SAPK/JNK Ab 
#9252; phospho-cJUN (Ser73) Ab#9164; cJUN mouse 
mAb #2315; phospho-p38 MAPK (Thr180/Tyr182) rabbit 
mAb #4511; phospho-ATF2 (Thr71) Ab #9221; ATF2 
rabbit mAb #9226; phospho-AKT (Ser473) #927; AKT Ab 
#9272; phospho-NF-κB p65 (Ser568) rabbit mAb #3033; 
NF-κB p65 rabbit mAb #4764; phospho-STAT3 (Tyr705) 
Ab #9131; STAT3 rabbit mAb #4904; p53 Ab #9282; 
BAX Ab #2772; PARP Ab #9542 and SOX2 Ab (#2748). 
The antibodies obtained from Cayman (Ann Arbor, MI) 
included CB1 receptor Ab #101500 and CB2 receptor Ab 
#101550. The secondary antibodies were conjugated to 
horseradish peroxidase; signals were detected using the 
ECL system (Thermo Scientific, Rockford, IL, USA).
ELISA for TNFα, TRAIL, IL6, IL8 and TGFβ1 
detection in the media
The ELISA kits for detection of human cytokines 
were from R&D System, Minneapolis, MN, USA and 
eBioscience, San Diego, CA, USA.
Luciferase reporter assay
TNF-promoter-luciferase reporter activity was 
determined in transiently transfected glioblastoma cells 
using-615TNFpr-Luc (wild type), two mutated constructs, 
-615TNFpr(mutCRE)-Luc and -615TNFpr(mutAP1)-
Luc, and -36TNFpr-Luc with “minimal” promoter, as 
previously described [64, 65] with small modifications. 
1.5 kb-TRAILpr-Luc reporter construct was also 
previously described [66]. Transient transfection of 
glioblastoma cells was performed using Lipofectamine 
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(Thermo Fisher Scientific). Luciferase activity was 
measured using a Dual-Luciferase Reporter Assay 
(Promega). Firefly luciferase activity of TNFpr or 
TRAILpr reporters was normalized to Renilla luciferase 
activity. Transfected cells were treated with 0.1% DMSO 
or 20 µM CBD for 6–18 hours. 
Expression dominant-negative constructs
Dominant-negative constructs pcDNA3-p38-ASP 
[97] and pcDNA3-JNK1-APF [98] used for regulation 
of apoptosis by in transiently transfected glioblastoma 
cells were also used in our previous studies [53, 54]. 
Cotransfection of glioblastoma cells by indicated 
expression constructs was performed in the presence 
of pcDNA3-GFP (5:1) using standard operating 
Lipofectamine procedure (Thermo Fisher Scientific).
RNA interference
U87MG cells were seeded at 100000 cells per well 
into six-well plates and grown for 24 h. Transfection of 
siRNA (50 nM) was performed using Lipofectamine 2000 
(Thermo Fisher Scientific). SignalSilence p38 MAPK 
siRNA (#6564) and SignalSilence control siRNA (#6568) 
from “Cell Signaling Technology” were used. Control 
siRNA (Fluorescein conjugate) (#6201) was added to both 
preparations (at ratio 1:5). 48 h after transfection, cells 
were treated by CBD for 6 h (for Western blot analysis) 
or 24 h for cell-cycle apoptosis analysis using PI staining 
of fixed cells and the subsequent FACS analysis of green 
transfected cells. 
 Quantitative real-time PCR
U87 and U118 cells were plated in 6-well plates and 
treated with CBD and/or radiation for indicated time. Cells 
were harvested using Trizol (Thermo Fisher Scientific) 
after washing twice with ice-cold PBS. RNA was extracted 
and converted to cDNA using High Capacity cDNA 
reverse transcription kit (Thermo Fisher Scientific). The 
QPCR probe sequences are listed in Table 1.
Gene expressions were measured by Life 
Technologies ViiA 7 Real-Time PCR System in standard 
mode. QPCR was analyzed using the comparative CT 
method (ΔΔCT Method). Beta-actin was used as reference 
gene. For each sample, the CT value of target gene was first 
normalized to the beta-actin CT value to obtain ΔCT. Then 
the ΔCT value was normalized to the control treatment 
(ctrl) within the same time-point to calculate ΔΔCT value. 
Showing in the graph is a 2-ΔΔCT value, which indicates the 
fold change of target gene mRNA levels against time-point 
control after normalization to reference gene. 
Suppression of cell signaling pathways by 
specific inhibitors
We performed specific inhibition of several 
signaling pathways using JNK1-3 inhibitor SP600125 (20 
µM), MAPK p38 inhibitor SB203580 (20 µM), IKK-NF-
κB inhibitor BMS345541 (10 µM); PI3K-AKT inhibitor 
LY294002 (50 µM); and MEK-ERK inhibitor U0126 (10 
µM). Western blotting with Abs to active forms of targeted 
proteins was used to evaluate the efficacy of inhibition. 
We assessed changes in apoptosis levels under these 
conditions. All inhibitors were dissolved in DMSO. 0.1% 
or 0.2% DMSO was used as a control vehicle. 
Statistical analyses of data 
Data from four to five independent experiments were 
calculated as means and standard deviations. Comparisons 
of results between treated and control groups were made 
by the Students’ t-tests. A p-value of 0.05 or less between 
groups was considered significant.
Abbreviations
AP1: activator protein 1; ATF2: activating 
transcription factor 2; CHX: cycloheximide; COX2: 
cyclooxygenase-2; ERK: extracellular signal-regulated 
kinase; FACS: fluorescence-activated cell sorter; FasL: 
Fas Ligand; IκB: inhibitor of NF-κB; IKK: inhibitor 
nuclear factor kappa B kinase; JNK: Jun N-terminal 
kinase; mAb: monoclonal Ab; Luc: luciferase; MAPK: 
mitogen-activated protein kinase; MEK: MAPK kinase; 
MEKK1: MAPK/ERK kinase: kinase-1; MFI: medium 
fluorescence intensity; NF-κB: nuclear factor kappa B; 
PARP: poly(ADP-ribose) polymerase; PI: propidium 
iodide; PI3K: phosphatidylinositol 3-kinase; ROS: 
reactive oxygen species; RNAi: RNA interference; 
STAT: signal transducer and activator of transcription; 
Table 1: QPCR primer sequences







TNFa: tumor necrosis factor alpha; TNFR: tumor 
necrosis factor receptor; TRAIL: TNF-related apoptosis-
inducing ligand; TRAIL-R: TRAIL-receptor; zVAD-fmk: 
benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone.
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